▁British 10.375
▁Bi 10.875
ote 5.60546875
ch 4.515625
' 7.375
s 1.0400390625
▁Mar 9.0078125
im 8.0078125
ast 9.171875
at 6.140625
▁Anti 9.1953125
- 0.91943359375
Can 6.93359375
cer 0.78515625
▁Tre 5.796875
at 1.8134765625
ment 1.1025390625
: 8.203125
▁A 4.45703125
▁Ray 9.6953125
▁of 3.12890625
▁Hope 5.80859375
▁to 4.90625
▁be 4.58984375
▁Review 7.8515625
ed 0.413818359375
▁at 4.859375
▁ES 11.1015625
MO 4.078125
▁Conference 5.89453125
▁in 3.9375
▁Vienna 6.83203125
<0x0A> 4.5390625
VI 8.640625
EN 0.305419921875
NA 0.0148162841796875
▁- 3.546875
▁In 3.96875
▁a 1.873046875
▁significant 6.5546875
▁development 1.7451171875
▁for 1.5302734375
▁the 1.0263671875
▁field 3.267578125
▁of 0.09600830078125
▁on 3.263671875
col 0.041015625
ogy 0.01300048828125
, 0.32177734375
▁British 7.60546875
▁ph 4.58203125
arma 0.04058837890625
ce 0.113525390625
ut 5.030632019042969e-05
ical 0.0016736984252929688
▁company 0.493408203125
▁British 6.53125
▁Bi 0.927734375
ote 0.0047607421875
ch 0.0220794677734375
▁announced 2.671875
▁that 1.1904296875
▁its 1.830078125
▁break 6.19140625
through 0.015716552734375
▁anti 3.3828125
- 0.0189666748046875
can 0.1702880859375
cer 0.0008530616760253906
▁treatment 1.3369140625
, 1.4736328125
▁Mar 7.07421875
im 1.0078125
ast 0.12457275390625
at 0.00598907470703125
, 0.328125
▁will 1.9853515625
▁be 0.387451171875
▁closely 9.2734375
▁exam 2.099609375
ined 0.003246307373046875
▁at 1.0791015625
▁the 0.56689453125
▁up 3.76171875
coming 0.00806427001953125
▁European 1.7021484375
▁Society 0.01337432861328125
▁for 0.69873046875
▁Medical 0.0169219970703125
▁On 0.020355224609375
col 0.0003476142883300781
ogy 2.0623207092285156e-05
▁( 0.444580078125
ES 0.006877899169921875
MO 0.00033473968505859375
) 0.02838134765625
▁conference 1.9404296875
▁in 0.802734375
▁Vienna 0.036468505859375
. 1.318359375
▁With 5.62109375
▁exper 7.328125
ts 0.0024700164794921875
▁from 0.912109375
▁around 1.8232421875
▁the 0.04254150390625
▁world 0.1513671875
▁gather 2.15625
ing 0.0017185211181640625
▁to 1.546875
▁discuss 0.5576171875
▁the 0.7666015625
▁latest 1.0859375
▁adv 1.9921875
anc 1.23046875
ements 0.0006303787231445312
▁in 0.1473388671875
▁on 1.494140625
col 0.02178955078125
ogy 0.0009670257568359375
▁research 2.427734375
, 0.329833984375
▁this 2.263671875
▁review 7.34375
▁holds 7.234375
▁promise 3.6484375
▁for 0.6904296875
▁the 1.3046875
▁future 0.85986328125
▁of 0.293701171875
▁cancer 0.88671875
▁treatment 0.492919921875
. 0.27294921875
<0x0A> 0.2069091796875
Mar 1.16015625
im 0.0042572021484375
ast 0.0033740997314453125
at 0.0009236335754394531
, 1.3505859375
▁a 0.9765625
▁novel 2.33203125
▁bi 4.734375
ote 1.7890625
chn 0.74169921875
ology 0.14697265625
▁drug 1.6025390625
, 1.0185546875
▁has 1.751953125
▁shown 1.7001953125
▁great 2.36328125
▁potential 2.81640625
▁in 0.66015625
▁advanced 8.015625
▁cancer 1.69140625
▁patients 1.5595703125
, 1.974609375
▁particularly 2.912109375
▁those 0.7021484375
▁suffering 2.212890625
▁from 0.0274810791015625
▁met 1.7509765625
ast 0.0028839111328125
atic 0.058502197265625
▁can 3.78125
cers 0.0007848739624023438
. 0.87939453125
▁British 5.75
▁Bi 0.013946533203125
ote 0.0001341104507446289
ch 0.048065185546875
' 1.53125
s 0.0010623931884765625
▁research 3.55078125
▁and 2.50390625
▁development 0.057891845703125
▁team 0.5029296875
▁has 1.42578125
▁conducted 3.984375
▁extensive 1.060546875
▁pre 2.8125
cl 0.34375
in 3.3736228942871094e-05
ical 0.0009698867797851562
▁tri 2.69140625
als 0.0001863241195678711
▁and 1.42578125
▁clin 1.91015625
ical 0.0012989044189453125
▁studies 0.87890625
, 1.7685546875
▁which 1.9443359375
▁have 0.69970703125
▁yield 3.28515625
ed 0.0007982254028320312
▁prom 1.001953125
ising 5.507469177246094e-05
▁results 0.1185302734375
. 0.595703125
▁As 4.23828125
▁a 0.69189453125
▁result 0.2081298828125
, 0.1553955078125
▁the 1.09375
▁ES 8.0859375
MO 0.003787994384765625
▁panel 4.36328125
▁has 1.65625
▁recognized 4.73046875
▁the 1.265625
▁need 2.166015625
▁to 0.8017578125
▁evaluate 3.0078125
▁the 0.9130859375
▁treatment 2.84375
' 1.966796875
s 0.00041675567626953125
▁effic 1.2783203125
acy 0.00014662742614746094
▁and 0.8125
▁potential 3.888671875
▁impact 3.07421875
▁on 0.319091796875
▁patient 2.47265625
▁out 1.1015625
comes 0.00350189208984375
. 0.58251953125
<0x0A> 0.3642578125
The 1.6064453125
▁drug 3.58203125
▁focus 9.1796875
es 0.001678466796875
▁on 0.026092529296875
▁in 3.439453125
hib 0.0160675048828125
iting 0.0270538330078125
▁a 2.470703125
▁specific 1.3037109375
▁en 1.15234375
zym 4.839897155761719e-05
e 0.003406524658203125
, 1.4365234375
▁matrix 8.125
▁metal 0.0263824462890625
lo 0.0015096664428710938
prote 0.021270751953125
in 0.10308837890625
ases 2.931640625
▁( 0.458740234375
M 0.042266845703125
MP 0.005329132080078125
s 0.3857421875
), 0.196044921875
▁which 0.320556640625
▁plays 3.85546875
▁a 0.379638671875
▁cru 1.904296875
cial 0.0003657341003417969
▁role 0.004383087158203125
▁in 0.002597808837890625
▁tum 2.470703125
or 0.07550048828125
▁growth 1.193359375
▁and 0.47802734375
▁met 0.49755859375
ast 0.0005536079406738281
asis 0.03558349609375
. 0.05328369140625
▁By 1.755859375
▁cont 6.62890625
rolling 0.00021517276763916016
▁the 1.06640625
▁activity 1.1142578125
▁of 0.0191497802734375
▁these 1.44140625
▁en 0.234375
zym 1.5854835510253906e-05
es 0.0019025802612304688
, 0.04296875
▁Mar 0.53662109375
im 0.0011692047119140625
ast 0.002330780029296875
at 0.00037932395935058594
▁may 1.8564453125
▁h 7.265625
inder 0.0080413818359375
▁cancer 1.62109375
▁cell 1.072265625
▁invasion 3.703125
▁and 0.35546875
▁decrease 7.0
▁the 0.95703125
▁pro 3.77734375
l 0.96044921875
ifer 0.00010061264038085938
ation 0.04229736328125
▁of 0.323486328125
▁tum 0.66357421875
ors 1.5986328125
. 0.26806640625
▁Research 4.75
ers 0.316162109375
▁believe 1.724609375
▁this 2.982421875
▁target 5.0625
ed 0.043548583984375
▁approach 0.99072265625
▁could 1.376953125
▁provide 2.771484375
▁a 1.0009765625
▁more 1.8720703125
▁effective 0.44970703125
▁alternative 3.185546875
▁to 0.1695556640625
▁conventional 2.06640625
▁cancer 2.041015625
▁treat 0.9541015625
ments 4.0531158447265625e-05
, 0.9853515625
▁such 1.103515625
▁as 0.0009288787841796875
▁chem 0.2607421875
other 0.0110321044921875
apy 0.027008056640625
. 1.7509765625
<0x0A> 0.1591796875
The 1.7265625
▁ES 1.75390625
MO 0.0009250640869140625
▁conference 1.4912109375
, 2.259765625
▁held 2.79296875
▁ann 1.197265625
ually 1.2993812561035156e-05
, 1.232421875
▁is 0.80029296875
▁known 4.6328125
▁for 0.60595703125
▁bringing 1.4111328125
▁together 0.0596923828125
▁exper 1.9453125
ts 5.9604644775390625e-06
, 4.45703125
▁top 7.33203125
▁research 1.1181640625
ers 0.0211334228515625
, 0.1722412109375
▁and 0.09619140625
▁health 3.857421875
care 0.331787109375
▁profession 0.1868896484375
als 5.7220458984375e-06
▁in 3.111328125
▁the 0.4775390625
▁field 0.513671875
▁of 0.078369140625
▁on 0.38818359375
col 0.0020236968994140625
ogy 1.4901161193847656e-05
. 0.317138671875
▁It 1.7666015625
▁serves 2.755859375
▁as 0.047943115234375
▁a 0.405517578125
▁platform 1.07421875
▁for 0.237060546875
▁sharing 1.5322265625
▁ground 5.96875
bre 0.144287109375
aking 2.1219253540039062e-05
▁research 0.94775390625
, 2.052734375
▁fost 4.73046875
ering 0.00478363037109375
▁collaboration 0.9052734375
, 0.283935546875
▁and 0.0178070068359375
▁en 4.484375
han 0.1624755859375
cing 1.3113021850585938e-06
▁the 1.5576171875
▁understanding 2.24609375
▁of 0.050811767578125
▁cancer 0.94091796875
▁bi 3.083984375
ology 0.006549835205078125
▁and 1.1083984375
▁ther 3.28515625
apy 0.5712890625
. 0.1319580078125
<0x0A> 1.4892578125
D 5.1015625
uring 0.515625
▁the 0.255126953125
▁conference 0.609375
, 0.025115966796875
▁British 1.2197265625
▁Bi 0.005222320556640625
ote 6.151199340820312e-05
ch 0.01030731201171875
▁is 3.62109375
▁scheduled 2.109375
▁to 0.0041961669921875
▁present 0.40380859375
▁clin 4.9296875
ical 0.004344940185546875
▁trial 1.302734375
▁data 0.9775390625
▁that 3.45703125
▁demonstr 2.4921875
ates 0.0001958608627319336
▁Mar 3.267578125
im 0.0007700920104980469
ast 0.004673004150390625
at 0.0008482933044433594
' 0.0257568359375
s 8.499622344970703e-05
▁initial 7.7734375
▁success 2.166015625
▁in 0.36767578125
▁patients 2.494140625
▁with 0.166259765625
▁various 4.67578125
▁forms 2.08203125
▁of 0.002185821533203125
▁cancer 0.72216796875
, 1.2138671875
▁including 0.220947265625
▁breast 1.71875
, 0.5166015625
▁lung 1.025390625
, 0.03216552734375
▁and 0.82421875
▁pan 2.2734375
cre 0.000274658203125
atic 0.1263427734375
▁can 0.73193359375
cers 6.413459777832031e-05
. 0.05108642578125
▁Pre 5.39453125
lim 0.19873046875
inary 0.0003108978271484375
▁find 1.6962890625
ings 1.1920928955078125e-07
▁suggest 1.6201171875
▁that 0.09710693359375
▁Mar 1.7060546875
im 0.0006799697875976562
ast 0.0016698837280273438
at 0.0003809928894042969
▁not 5.15234375
▁only 0.00396728515625
▁exhib 4.90234375
its 0.11212158203125
▁anti 2.09375
- 0.00415802001953125
t 0.75
um 6.198883056640625e-06
oral 5.19921875
▁benefits 6.84375
▁but 0.8955078125
▁also 0.10540771484375
▁ass 9.7109375
ists 0.0183563232421875
▁in 0.289306640625
▁reducing 2.462890625
▁cancer 3.03515625
- 0.57177734375
associ 2.541015625
ated 3.1948089599609375e-05
▁sympt 1.724609375
oms 0.0037364959716796875
, 1.00390625
▁impro 5.26953125
ving 0.11480712890625
▁patients 2.419921875
' 0.003353118896484375
▁quality 0.16650390625
▁of 0.0107574462890625
▁life 0.0019407272338867188
. 1.955078125
<0x0A> 0.3193359375
Comment 6.33984375
ing 0.016571044921875
▁on 0.0031642913818359375
▁the 0.1788330078125
▁significance 2.994140625
▁of 0.0128173828125
▁show 11.0546875
c 0.0022487640380859375
asing 0.0005583763122558594
▁Mar 0.8515625
im 0.0004992485046386719
ast 0.0023651123046875
at 0.0005016326904296875
▁at 0.51318359375
▁the 0.5556640625
▁ES 0.5244140625
MO 0.0014495849609375
▁conference 0.1190185546875
, 0.036529541015625
▁Dr 1.3544921875
. 0.052398681640625
▁Am 5.3984375
anda 2.376953125
▁Rod 7.01171875
rig 0.849609375
uez 0.84033203125
, 0.2049560546875
▁Chief 2.451171875
▁Medical 0.61962890625
▁Officer 0.044708251953125
▁at 0.8662109375
▁British 0.0251617431640625
▁Bi 0.0031070709228515625
ote 3.421306610107422e-05
ch 0.00806427001953125
, 0.08544921875
▁stated 1.5791015625
, 0.70947265625
▁" 0.03131103515625
We 1.171875
▁are 0.1995849609375
▁thr 2.302734375
illed 2.8848648071289062e-05
▁to 0.10626220703125
▁have 1.24609375
▁the 0.921875
▁opportunity 0.16796875
▁to 0.005126953125
▁present 0.88818359375
▁our 1.3134765625
▁research 3.6796875
▁find 1.2646484375
ings 9.5367431640625e-07
▁on 2.98046875
▁Mar 0.9296875
im 0.0002319812774658203
ast 0.0015439987182617188
at 0.00014960765838623047
▁at 0.487548828125
▁such 3.654296875
▁a 0.5341796875
▁pr 0.281005859375
estig 5.7220458984375e-06
ious 2.7060508728027344e-05
▁event 1.146484375
. 0.39599609375
▁This 1.6484375
▁validation 6.875
▁from 3.5859375
▁the 0.9814453125
▁scientific 3.552734375
▁community 0.08636474609375
▁further 3.376953125
▁motiv 6.98046875
ates 0.0006818771362304688
▁us 0.20556640625
▁to 0.03826904296875
▁continue 0.6552734375
▁our 0.859375
▁purs 3.333984375
uit 0.00986480712890625
▁of 0.1463623046875
▁impro 3.00390625
ving 2.968311309814453e-05
▁cancer 1.4130859375
▁treatment 0.6708984375
▁options 1.859375
▁and 2.517578125
▁patients 6.30859375
' 0.00989532470703125
▁lives 1.833984375
." 0.271484375
<0x0A> 0.0391845703125
Wh 5.29296875
ile 0.025543212890625
▁the 1.259765625
▁road 9.03125
▁to 0.71240234375
▁regul 5.06640625
atory 0.0005087852478027344
▁appro 0.05889892578125
val 1.2993812561035156e-05
▁and 2.76171875
▁w 2.251953125
ides 9.799003601074219e-05
p 0.0011148452758789062
read 0.00014793872833251953
▁avail 1.8916015625
ability 0.00022554397583007812
▁is 1.55859375
▁still 0.640625
▁long 1.6337890625
, 0.4619140625
▁the 1.56640625
▁high 6.62890625
- 1.8828125
profile 1.28515625
▁show 5.4609375
case 0.56201171875
▁at 1.0595703125
▁ES 0.8134765625
MO 0.0010662078857421875
▁provides 3.046875
▁British 1.7255859375
▁Bi 0.0021266937255859375
ote 3.635883331298828e-05
ch 0.0015106201171875
▁with 0.171875
▁a 1.021484375
▁unique 3.158203125
▁opportunity 0.1656494140625
▁to 0.01496124267578125
▁eng 4.2109375
age 0.00048351287841796875
▁with 0.28271484375
▁leading 1.974609375
▁on 1.755859375
colog 1.9111328125
ists 0.018402099609375
, 1.4423828125
▁research 1.4931640625
ers 0.03375244140625
, 0.019012451171875
▁and 0.059417724609375
▁decision 3.7734375
- 0.333740234375
m 0.003978729248046875
akers 0.00011599063873291016
▁in 1.4169921875
▁the 0.09735107421875
▁field 0.546875
▁of 1.1591796875
▁cancer 1.1142578125
▁th 5.6640625
era 0.0001990795135498047
pe 1.800060272216797e-05
ut 2.86102294921875e-05
ics 0.0020008087158203125
. 0.1141357421875
▁This 2.15625
▁event 2.65234375
▁could 4.87890625
▁potentially 2.619140625
▁lead 1.4716796875
▁to 0.0116729736328125
▁prom 6.24609375
ising 0.0009889602661132812
▁collabor 2.783203125
ations 0.08642578125
, 2.078125
▁thereby 6.5625
▁exp 7.71484375
edit 0.00445556640625
ing 0.00018405914306640625
▁the 0.261962890625
▁path 3.306640625
▁of 3.51953125
▁Mar 0.72607421875
im 0.0002086162567138672
ast 0.0015773773193359375
at 0.00028896331787109375
▁towards 3.4453125
▁clin 3.08203125
ical 0.006732940673828125
▁application 2.42578125
. 0.21337890625
<0x0A> 0.080078125
The 3.115234375
▁ES 1.310546875
MO 0.0018777847290039062
▁conference 0.29931640625
, 2.064453125
▁taking 4.0859375
▁place 0.0014171600341796875
▁from 0.876953125
▁September 1.6376953125
▁ 0.0014286041259765625
1 1.01953125
8 2.208984375
- 0.8837890625
2 0.006969451904296875
2 0.5341796875
, 0.34814453125
▁will 1.478515625
▁see 3.75
▁over 1.6923828125
▁ 0.01273345947265625
2 1.814453125
5 1.900390625
, 0.2420654296875
0 0.007442474365234375
0 2.3484230041503906e-05
0 0.0011157989501953125
▁research 3.859375
ers 0.0755615234375
, 0.361083984375
▁clin 1.5107421875
icians 0.050567626953125
, 0.045135498046875
▁and 0.2548828125
▁industry 1.958984375
▁exper 1.8896484375
ts 6.639957427978516e-05
▁coming 4.8828125
▁together 0.0125732421875
▁to 0.1097412109375
▁discuss 0.6240234375
▁the 0.33447265625
▁latest 0.11236572265625
▁adv 0.54638671875
anc 0.1905517578125
ements 2.2292137145996094e-05
▁in 0.04974365234375
▁on 0.74365234375
col 0.006778717041015625
ogy 1.1086463928222656e-05
▁research 0.53857421875
▁and 1.330078125
▁treatment 0.6103515625
▁strateg 4.19921875
ies 1.3828277587890625e-05
. 0.042999267578125
▁A 4.8046875
part 2.611328125
▁from 0.0003979206085205078
▁Mar 1.765625
im 0.0004379749298095703
ast 0.0017938613891601562
at 0.00014603137969970703
, 0.036163330078125
▁numerous 4.3046875
▁other 0.453369140625
▁ground 3.6328125
bre 0.1392822265625
aking 2.288818359375e-05
▁ther 3.169921875
ap 0.007354736328125
ies 4.315376281738281e-05
▁and 1.7861328125
▁novel 4.0625
▁approaches 1.734375
▁will 1.0595703125
▁be 0.16748046875
▁expl 3.66796875
ored 0.0008897781372070312
▁during 1.8251953125
▁the 0.1795654296875
▁event 1.439453125
. 0.250244140625
<0x0A> 0.50732421875
As 3.97265625
▁the 1.5107421875
▁conference 2.9765625
▁approaches 2.880859375
, 0.04364013671875
▁the 2.7734375
▁anticip 6.45703125
ation 0.245849609375
▁surrounding 2.220703125
▁British 1.0986328125
▁Bi 0.001926422119140625
ote 3.635883331298828e-05
ch 0.0018291473388671875
' 0.045196533203125
s 0.00027060508728027344
▁Mar 1.669921875
im 0.0005755424499511719
ast 0.001678466796875
at 0.00018453598022460938
▁continues 2.60546875
▁to 0.0170745849609375
▁build 1.4638671875
. 0.270751953125
▁The 1.9345703125
▁spot 9.9765625
light 0.0005793571472167969
▁will 1.1298828125
▁shift 4.89453125
▁to 0.72900390625
▁Vienna 2.58984375
, 1.2958984375
▁where 0.822265625
▁this 4.1015625
▁potentially 5.5546875
▁ground 1.6162109375
bre 0.1348876953125
aking 5.602836608886719e-05
▁anti 2.9296875
- 0.00115966796875
can 0.07958984375
cer 0.0002276897430419922
▁treatment 0.422607421875
▁will 0.29345703125
▁be 0.243408203125
▁exam 2.736328125
ined 5.6862831115722656e-05
, 4.29296875
▁evaluated 1.599609375
, 0.033782958984375
▁and 0.021270751953125
▁potentially 2.751953125
▁p 7.1953125
ave 1.6962890625
▁the 0.03680419921875
▁way 0.057159423828125
▁for 0.26904296875
▁new 3.173828125
▁v 9.984375
istas 1.130859375
▁in 0.3544921875
▁the 1.7421875
▁fight 2.591796875
▁against 0.005176544189453125
▁cancer 0.11669921875
. 0.033538818359375
